CRS's PDUFA report documenting that industry user fees fund more than 60% of FDA's human drug review budget (per FDA official testimony), the structural funding link between industry and the regulator.
user fees have come to provide more than 60% of FDA's drug review budget
CRS's PDUFA report documenting that industry user fees fund more than 60% of FDA's human drug review budget (per FDA official testimony), the structural funding link between industry and the regulator. CRS attributes the share figure to FDA testimony; the report also describes the statutory framework and reauthorization history.